Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Astrocytoma, IDH-mutant (grades 2 to 4), drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether vorasidenib should replace radiotherapy and chemotherapy or only defer them, and what to do at progression on it.
No IDH inhibitor has yet shown benefit in grade 3 or 4 IDH-mutant astrocytoma.
Cognitive decline after radiotherapy in people who live decades with the disease.
Temozolomide-induced hypermutation at recurrence has no specific treatment.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12 (INDIGO): first targeted therapy for low-grade glioma
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12
A milestone in how this cancer is treated.
PFS 27.
Mellinghoff and colleagues (NEJM): median progression-free survival 27.7 versus 11.1 months.